Serum NGAL to Clinically Distinguish Cholangiocarcinoma from Benign Biliary Tract Diseases

Serum NGAL to Clinically Distinguish Cholangiocarcinoma from Benign Biliary Tract Diseases

Aim. To determine whether the serum level of NGAL can discriminate cholangiocarcinoma from benign biliary tract disease in patients. Methods. This study was performed according to a prospective-specimen-collection, retrospective-blinded-evaluation (PRoBE) design. A total of 50 cholangiocarcinoma an...

Full description

Saved in:
Bibliographic Details
Main Authors: Kawin Leelawat, Siriluck Narong, Jerasak Wannaprasert, Surang Leelawat
Format: Article
Language:English
Published: Wiley 2011-01-01
Series:International Journal of Hepatology
Online Access:http://dx.doi.org/10.4061/2011/873548
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items